vTv Therapeutics Inc. (VTVT) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$26.70

From 52W high−36.94%

Volume17912.00

Market cap$106.52M

P/E (TTM)—

P/S (TTM)2.9x

Div yield—

Key dataOct 19, 2026

Open

$26.70

From 52W high

−36.94%

Volume

17912.00

Market cap

$106.52M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.1x

P/E (TTM)

—

RSI (14)

33.8

MomentumView details →

1D Return

+1.51%

YTD Return

−32.65%

SummaryUpdated Jun 1, 2026

vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in High Point, North Carolina. The company operates as a subsidiary of MacAndrews & Forbes Incorporated and focuses on developing orally administered treatments primarily for diabetes and other metabolic disorders. Since its initial public offering in July 2015, vTv has been advancing a pipeline of small molecule therapeutics through various stages of clinical development, with particular emphasis on innovative approaches to treating type 1 diabetes and inflammatory conditions.

Ask drillr about vTv Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.1x

EV/Sales

0.5x

P/S (TTM)

2.9x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−12.91%

EBITDA Margin

−17.35%

ROE (TTM)

−6.05%

ROA (TTM)

−5.43%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

—

EPS YoY

+96.56%

FCF YoY

+23.90%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+0.00%

EBITDA YoY

+73.17%

MomentumView details →

1D Return

+1.51%

YTD Return

−32.65%

1Y Return

+30.69%

RSI (14)

33.8

vs 50D SMA

−13.99%

vs 200D SMA

−21.00%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.48x

Quick Ratio

12.48x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.05

EPS Surprise

−8.25%

Beats (12Q)

6/12

Next Q EPS Est

−$1.11

Avg Surprise (4Q)

103.10%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

36.84M

Net Income (TTM)

−4.76M

Op. CF (TTM)

−16.76M

Next earningsNov 5, 2026 →

Latest newsMore news →

The FDA granted orphan drug designation to vTv Therapeutics Inc.’ HPPD for sickle cell disease.12d ago

vTv Therapeutics completed enrollment in its Phase 3 CATT1 study of Cadisegliatin in Type 1 Diabetes, with topline results expected in mid-2027.15d ago

Similar companies

enGene Holdings Inc.ENGN Vaxart, Inc.VXRT Black Diamond Therapeutics, Inc.BDTX LENZ Therapeutics, Inc.LENZ Humacyte, Inc.HUMA Inovio Pharmaceuticals, Inc.INO Find similar companies →

Latest newsMore news →

The FDA granted orphan drug designation to vTv Therapeutics Inc.’ HPPD for sickle cell disease.12d ago vTv Therapeutics completed enrollment in its Phase 3 CATT1 study of Cadisegliatin in Type 1 Diabetes, with topline results expected in mid-2027.15d ago